Back to Search
Start Over
Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
- Source :
-
Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2024 May; Vol. 76 (5), pp. 796-805. Date of Electronic Publication: 2024 Feb 06. - Publication Year :
- 2024
-
Abstract
- Objective: Interferon-λ3 (IFNλ3) is a cytokine with antiviral functions on barrier surfaces, and it is associated with disease activity in autoimmune diseases. This study assessed the clinical significance of serum IFNλ3 levels in polymyositis/dermatomyositis (PM/DM)-associated interstitial lung disease (ILD).<br />Methods: We measured serum IFNλ3 levels in 221 patients with PM/DM-ILD (155 in the derivation cohort, 66 in the validation cohort) and 38 controls. We evaluated factors associated with mortality risk among 79 patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive DM-ILD.<br />Results: Serum IFNλ3 levels at diagnosis were significantly higher in patients with PM/DM-ILD than in healthy controls. Remarkably, serum IFNλ3 levels were specifically increased in patients with anti-MDA5 antibody-positive DM-ILD in both the derivation and validation cohorts. In anti-MDA5 antibody-positive DM-ILD, patients with high IFNλ3 levels (>120 pg/mL) had significantly lower survival rates than those with low IFNλ3 levels (≤120 pg/mL). A multivariate analysis revealed that high IFNλ3 levels, as well as old age and low Pao <subscript>2</subscript> , were significantly associated with poor prognoses in patients with anti-MDA5 antibody-positive DM-ILD. In a classification analysis of patients with anti-MDA5 antibody-positive DM-ILD based on age, IFNλ3 level, and Pao <subscript>2</subscript> , patients with old age (>53 years), high IFNλ3 levels (>120 pg/mL), and low Pao <subscript>2</subscript> (<75 mm Hg) had the worst survival. In lung pathologic analyses, IFNλ3-positive staining was observed in macrophages, airway epithelial cells, the pleural region, and intrapulmonary veins in patients with anti-MDA5 antibody-positive DM-ILD.<br />Conclusion: Serum IFNλ3 is a promising biomarker for identifying patients at high risk of poor outcomes in anti-MDA5 antibody-positive DM-ILD.<br /> (© 2023 American College of Rheumatology.)
- Subjects :
- Humans
Male
Female
Middle Aged
Prognosis
Aged
Interferons
Adult
Interleukins blood
Case-Control Studies
Lung Diseases, Interstitial immunology
Dermatomyositis immunology
Dermatomyositis complications
Dermatomyositis blood
Interferon-Induced Helicase, IFIH1 immunology
Autoantibodies blood
Autoantibodies immunology
Interferon Lambda
Subjects
Details
- Language :
- English
- ISSN :
- 2326-5205
- Volume :
- 76
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Arthritis & rheumatology (Hoboken, N.J.)
- Publication Type :
- Academic Journal
- Accession number :
- 38146102
- Full Text :
- https://doi.org/10.1002/art.42785